RedHill Biopharma (2RH) AI Stock Analysis

RedHill Biopharma

(Frankfurt:2RH)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Expanded GI Commercial PlatformThe rights acquisition gives RedHill access to established, FDA-approved GI products with reported prior sales, payer coverage and a long initial term. This materially broadens the commercial base and could support more durable revenue generation than the company’s prior portfolio.

Negative Factors

Severe Revenue and Profitability DeteriorationThe sharp top-line contraction and recurring operating losses indicate that historical earnings are not durable and that the prior business model has not generated consistent scale. Rebuilding revenue through the new portfolio will be important before profitability can become dependable.

RedHill Biopharma (2RH) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.22M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.9
Beta (1Y): ―
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 13
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

RedHill Biopharma Business Overview & Revenue Model

Company Description

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioi...

RedHill Biopharma Risk Analysis

RedHill Biopharma disclosed 86 risk factors in its most recent earnings report. RedHill Biopharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Our limited operating history, especially under current COVID-19 pandemic conditions, makes it difficult to evaluate our business and prospects.Q4, 2021

2.The license agreements we maintain, including our license agreement with Cosmo, may be amended or terminated. If we or the other parties to our license agreements amend or terminate the license agreements, the development, testing, manufacture, production and sale of our products or product candidates may be delayed or terminated, and our business may be adversely affected.Q4, 2021

3.Supply chain and shipping disruptions may result in shipping delays, a significant increase in shipping costs, and could increase product costs and result in lost sales and reputational damage, which may have a material adverse effect on our business, operating results and financial condition.Q4, 2021

RedHill Biopharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:2RH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TAK	67Neutral	$67.38B	27.16	5.07%	3.00%	0.67%	-12.01%
TEVA	65Neutral	$47.43B	70.17	9.18%	―	4.40%	―
IRWD	64Neutral	$578.34M	4.40	-57.40%	―	26.19%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SIGA	47Neutral	$218.42M	-69.72	-1.53%	―	-70.13%	-103.41%
PRGO	46Neutral	$2.19B	-1.26	-55.97%	7.35%	-4.18%	-2138.82%

* Healthcare Sector Average

Performance Comparison

DE:2RH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:2RH	RedHill Biopharma Ltd	8.00	0.00	0.00%
IRWD	Ironwood Pharmaceuticals	3.50	1.64	88.17%
PRGO	Perrigo Company	15.78	-2.98	-15.89%
SIGA	Siga Technologies	3.04	-4.21	-58.09%
TEVA	Teva Pharmaceutical Industries Limited	42.09	23.59	127.51%
TAK	Takeda Pharmaceutical Company	20.91	7.49	55.81%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

RedHill Biopharma AI Stock Analysis